Skip to main content
AngioLab, Inc. logo

AngioLab, Inc. — Investor Relations & Filings

Ticker · 251280 ISIN · KR7251280004 KO Professional, scientific and technical activities
Open in API
Filings indexed 173 across all filing types
Latest filing 2024-03-27 Major Shareholding Noti…
Country KR South Korea
Listing KO 251280

About AngioLab, Inc.

https://angiolab.co.kr/

AngioLab, Inc. is a biotechnology company specializing in the discovery and development of angiogenesis inhibitors. The company develops pharmaceuticals and health functional foods to treat diseases associated with the abnormal growth of blood vessels. Its pipeline includes drug candidates targeting conditions such as age-related macular degeneration (AMD), with some candidates having undergone Phase II clinical trials. AngioLab has also developed Ob-X, a functional food ingredient based on its anti-angiogenic research platform.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (DART system) used when an entity's shareholding in a company crosses a specific threshold (typically 5%). This document details the shareholding changes of Shinhan Venture Investment in Angiolab. It is a formal regulatory disclosure of ownership, not an announcement of a report, and fits the definition of a Major Shareholding Notification.
2024-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal announcement titled '감사보고서 제출' (Submission of Audit Report) dated 2024.03.20. It provides a summary of the audit opinion (적정/Unqualified) and key financial highlights (assets, liabilities, revenue, etc.) as reported by the external auditor (삼일회계법인). Since this is a standalone regulatory filing announcing the submission of the audit report rather than the full annual report document itself, it falls under the category of Audit Report / Information. FY 2023
2024-03-20 Korean
사업보고서 (2023.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the fiscal year 2023 (Jan 1, 2023 - Dec 31, 2023) submitted to the Financial Supervisory Service and the Korea Exchange. In the context of Korean corporate filings, the 'Business Report' is the equivalent of the US 10-K, containing comprehensive financial statements, business operations, governance, and management analysis. Therefore, it is classified as a 10-K. FY 2023
2024-03-20 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for AngioLab, dated March 13, 2024. It contains the meeting agenda, details on voting, and management information (such as director activities and remuneration). While it contains some financial information, it is primarily a proxy statement/notice for shareholders to attend the AGM and vote on agenda items. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category, as it serves to inform shareholders and request their participation/votes for the upcoming meeting.
2024-03-13 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집 결의) issued by AngioLab. It outlines the date, time, location, and the agenda items (such as approval of financial statements and director compensation) to be voted on at the upcoming meeting. This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2024-03-08 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically marked as a '정정신고' (Correction Report). It details changes to previously granted stock options, including adjustments to the number of shares and the list of recipients. In the context of financial filings, reports regarding stock option grants, especially those involving corrections or amendments to capital-related instruments, are classified under 'Regulatory Filings' (RNS) as they represent specific corporate disclosures to regulatory bodies that do not fit into the more specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital issuance).
2024-02-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.